One year in review 2018: progress in osteoporosis treatment

Clin Exp Rheumatol. 2018 Nov-Dec;36(6):948-958. Epub 2018 Dec 6.

Abstract

Osteoporosis is a generalised bone disease characterised by decreased bone mass and deterioration of bone microarchitecture predisposing to fragility fractures. Bone fractures are a remarkable social and economic health problem, and several studies have been carried out in order to reduce their occurrence. Inhibiting bone resorption and increasing bone formation are the mainstay of treatment, anti-catabolic and anabolic, respectively. This review highlights the most recent advances in osteoporosis and reports the evidence of efficacy and safety of anabolic treatment of osteoporosis, as evaluated by randomised, controlled trials published during 2017. As the most common form of secondary osteoporosis, we will also discuss the 2017 state-of-the-art on pathogenesis and treatment of glucocorticoid-induced osteoporosis.

Publication types

  • Review

MeSH terms

  • Animals
  • Biomarkers / blood
  • Bone Density / drug effects
  • Bone Density Conservation Agents / adverse effects
  • Bone Density Conservation Agents / therapeutic use*
  • Bone Remodeling / drug effects*
  • Bone and Bones / drug effects*
  • Bone and Bones / metabolism
  • Bone and Bones / physiopathology
  • Glucocorticoids / adverse effects
  • Humans
  • Osteoporosis / blood
  • Osteoporosis / chemically induced
  • Osteoporosis / drug therapy*
  • Osteoporosis / physiopathology
  • Osteoporotic Fractures / blood
  • Osteoporotic Fractures / physiopathology
  • Osteoporotic Fractures / prevention & control*
  • Risk Factors
  • Treatment Outcome

Substances

  • Biomarkers
  • Bone Density Conservation Agents
  • Glucocorticoids